Study subjects characteristics from both cohorts (n=175)
| Patient characteristics | PSC only (n=18) | PSC-UC (n=27) | PSC-CD (n=21) | UC (n=13) | CD (n=30) | Healthy controls (n=66) |
|---|---|---|---|---|---|---|
| Male (%) | 10 (55.6) | 20 (74) | 18 (85.7) | 4 (30.8) | 15 (50) | 49 (74) |
| Median (IQR) age (years) | 49 (15.25) | 43 (14) | 49 (17) | 50 (28) | 52 (14.25) | 51.5 (17) |
| Median (IQR) BMI (kg/m²) | 23.45 (8.25) | 23.7 (6.2) | 23.5 (5.2) | 25.6 (4.9) | 25.25 (5.4) | 23.72 (4.9) |
| Current smoker (%) | 1 (5.6) | 1 (3.7) | 7 (33.3) | 2 (15.4) | 11 (36.7) | 4 (7.7) |
| Median (IQR) age (years) at diagnosis of PSC | 37.5 (15) | 32 (8.5) | 35 (21) | NA | NA | NA |
| Liver transplantation (%) | 7 (38.9) | 7 (25.9) | 1 (4.8) | 0 (0) | 0 (0) | 0 (0) |
| Cirrhosis (%) | 1 (5.6) | 7 (25.9) | 5 (23.8) | 0 (0) | 0 (0) | 0 (0) |
| Pouch (%) | 0 (0) | 4 (14.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Calprotectin (µg/g)—median (IQR) | 100 (226.1) | 121 (406) | 339 (1081.95) | NA | 132.5 (214.25) | NA |
| CRP (mg/L)- median (IQR) | 1.4 (3.6) | 2.25 (3.975) | 2.05 (7.15) | 2.2 (3.8) | 2.1 (2.7) | 0.7 (1.3) |
| IBD activity score—median (IQR) | NA | 0 (2) | 1 (4.25) | 2 (3) | 3 (4) | NA |
| Medications | ||||||
| UDCA (%) | 13 (72.2) | 18 (66.7) | 16 (76.2) | 0 (0) | 1 (3.3) | 0 (0) |
| 5-Amminosalicylates (%) | 0 (0) | 18 (66.7) | 4 (19) | 12 (92.3) | 2 (6.7) | 0 (0) |
| Corticosteroids (%) | 3 (16.7) | 3 (11.1) | 2 (9.5) | 3 (23) | 1 (3.3) | 0 (0) |
| Immunosuppression (%) | 8 (44.4) | 7 (25.9) | 4 (19) | 4 (30.8) | 8 (26.7) | 0 (0) |
| Anti-TNF α (%) | 0 (0) | 5 (18.5) | 8 (38) | 3 (23) | 16 (53.3) | 0 (0) |
| Antibiotics in the last month (%) | 2 (11.8) | 4 (16.7) | 5 (26.3) | 0 (0) | 0 (0) | 0 (0) |
| Probiotics in the last month (%) | 1 (6.7) | 3 (13) | 3 (18.7) | 0 (0) | 5 (20,8) | 2 (3) |
BMI, body mass index; CD, Crohn's disease; PSC, primary sclerosing cholangitis; UC, ulcerative colitis; UDCA, ursodeoxycholic acid.